NCT01509677 - Trial to Assess the Anti-inflammatory Effects of Roflumilast in Chronic Obstructive Pulmonary Disease | Biotech Hunter

Enrollment

158

Participants

Timeline

Start Date

February 1, 2012

Primary Completion Date

February 1, 2016

Study Completion Date

February 1, 2016

Conditions

COPDChronic Obstructive Pulmonary Disease

Interventions

DRUG

Roflumilast

500 μg tablet, once daily, oral administration in the morning after breakfast

DRUG

Placebo

tablet, once daily, oral administration in the morning after breakfast

Trial Locations (20)

København NV

København NV

Freiburg im Breisgau

Großhansdorf

Hanover

Heidelberg

Immenhausen

Kiel

Mainz

Bialystok

Krakow

Lodz

Lund

Cottingham

Dafen

Leicester

London

Manchester

Lodz

Norwich